UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

Cancer science, 2020-12, Vol.111 (12), p.4526-4539

2020

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM

Cancer science, 2020-06, Vol.111 (6), p.2116-2122

2020

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

Cancer science, 2015-11, Vol.106 (11), p.1561-1567

2015

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

Cancer science, 2019-09, Vol.110 (9), p.2924-2932

2019

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan

Cancer science, 2017-03, Vol.108 (3), p.461-468

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial

Acta medica Okayama, 2019-12, Vol.73 (6), p.547-552

2019

Link zum Volltext

Verfügbarkeit prüfen

Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)

Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1059-1066

2021

Link zum Volltext

Verfügbarkeit prüfen

Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era

Cancer science, 2015-02, Vol.106 (2), p.179-185

2015

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study

International journal of hematology, 2013-08, Vol.98 (2), p.179-185

2013

Link zum Volltext

Verfügbarkeit prüfen

Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group

International journal of hematology, 2014-05, Vol.99 (5), p.644-651

2014

Link zum Volltext

Verfügbarkeit prüfen

Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups

International journal of hematology, 2013, Vol.97 (1), p.98-102

2013

Link zum Volltext

Verfügbarkeit prüfen

Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma

Cancer science, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8025-8025

2022

Link zum Volltext

Verfügbarkeit prüfen

Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation

Biology of blood and marrow transplantation, 2015-07, Vol.21 (7), p.1291-1298

2015

Link zum Volltext

Verfügbarkeit prüfen

A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

Experimental hematology & oncology, 2016-04, Vol.5 (11), p.11-11, Article 11

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical evaluation of cefozopran as treatment for febrile neutropenia

Gan to kagaku ryoho, 2004-01, Vol.31 (1), p.61

2004

Link zum Volltext

Verfügbarkeit prüfen

Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study

The American journal of gastroenterology, 2023-07, Vol.118 (7), p.1248-1255

2023

Link zum Volltext

Verfügbarkeit prüfen

Crohn's Disease-Associated Anorectal Cancer Has a Poor Prognosis With High Local Recurrence: A Subanalysis of the Nationwide Japanese Study

The American journal of gastroenterology, 2023-09, Vol.118 (9), p.1626-1637

2023

Link zum Volltext

Verfügbarkeit prüfen

Reviewers

Cancer science, 2023-12, Vol.114 (12), p.4770-4775

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II study of bortezomib‐melphalan‐prednisolone for previously untreated Japanese patients with multiple myeloma

Cancer science, 2013-07, Vol.104 (7), p.912-919

2013

Link zum Volltext

Verfügbarkeit prüfen

Author Index

Journal of cardiac failure, 2015, Vol.21 (10), p.S206-S214

2015

Link zum Volltext

Verfügbarkeit prüfen

Author Index

Journal of cardiac failure, 2014, Vol.20 (10), p.S211-S220

2014

Link zum Volltext

Verfügbarkeit prüfen

Author Index

Journal of cardiac failure, 2016, Vol.22 (9), p.S234-S244

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(29)

Sprache

Englisch
(28)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan

Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial

Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)

Central nervous system event in patients with diffuse large B‐cell lymphoma in the rituximab era

Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era

Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study

Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group

Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups

Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

Five‐year follow‐up of a phase II study of DA‐EPOCH‐R with high‐dose MTX in CD5‐positive DLBCL

Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation

A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

Clinical evaluation of cefozopran as treatment for febrile neutropenia

Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study

Crohn's Disease-Associated Anorectal Cancer Has a Poor Prognosis With High Local Recurrence: A Subanalysis of the Nationwide Japanese Study

Reviewers

Phase I/II study of bortezomib‐melphalan‐prednisolone for previously untreated Japanese patients with multiple myeloma

Author Index

Author Index

Author Index

Aktive Filter

Suchergebnisse filtern